MoonLake Immunotherapeutics Past Earnings Performance
Past criteria checks 0/6
MoonLake Immunotherapeutics has been growing earnings at an average annual rate of 15.9%, while the Biotechs industry saw earnings growing at 15.9% annually.
Key information
15.9%
Earnings growth rate
42.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -8.3% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
May 14
MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3
Feb 26We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn
Jan 29Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
Oct 16Vetter Pharma to provide fill and finish services to MoonLake Immunotherapeutics
Jul 26Revenue & Expenses Breakdown
How MoonLake Immunotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -41 | 24 | 37 |
| 31 Dec 23 | 0 | -36 | 22 | 32 |
| 30 Sep 23 | 0 | -46 | 21 | 35 |
| 30 Jun 23 | 0 | -46 | 21 | 37 |
| 31 Mar 23 | 0 | -48 | 23 | 39 |
| 31 Dec 22 | 0 | -50 | 23 | 42 |
| 30 Sep 22 | 0 | -58 | 31 | 38 |
| 30 Jun 22 | 0 | -54 | 30 | 4 |
Quality Earnings: MLTX is currently unprofitable.
Growing Profit Margin: MLTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if MLTX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare MLTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MLTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: MLTX has a negative Return on Equity (-8.3%), as it is currently unprofitable.